Abg Innovation Capital Partners Iii Gp LTD Castle Biosciences Inc Transaction History
Abg Innovation Capital Partners Iii Gp LTD
- $1.06 Million
- Q4 2024
A detailed history of Abg Innovation Capital Partners Iii Gp LTD transactions in Castle Biosciences Inc stock. As of the latest transaction made, Abg Innovation Capital Partners Iii Gp LTD holds 36,747 shares of CSTL stock, worth $754,048. This represents 92.1% of its overall portfolio holdings.
Number of Shares
36,747
Previous 36,747
-0.0%
Holding current value
$754,048
Previous $1.05 Million
6.58%
% of portfolio
92.1%
Previous 95.1%
Shares
4 transactions
Others Institutions Holding CSTL
# of Institutions
210Shares Held
26.6MCall Options Held
128KPut Options Held
35.4K-
Black Rock Inc. New York, NY3.04MShares$62.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.83MShares$37.6 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.8MShares$36.9 Million0.24% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.44MShares$29.5 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX999KShares$20.5 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $540M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...